DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9.241,773 B2 Bolan Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9.241,773 B2 Bolan Et Al US009241773B2 (12) United States Patent (10) Patent No.: US 9.241,773 B2 Bolan et al. (45) Date of Patent: *Jan. 26, 2016 (54) MAGING FIDUCALMARKERS AND A61B 2019/547; A61B 2019/5408: A61B METHODS 2019/5425; A61B 2019/5454: A61B 2019/5495; A61B 2019/5458: A61B (71) Applicant: Breast-Med, Inc., Golden Valley, MN 2019/5466; G01R 33/4814; G01 R33/5601; (US) A61M31/005; A61K 49/0002: A61 K (72) Inventors: Patrick Bolan, Minneapolis, MN (US); 49/0447; A61K 49/18: A61K 49/226; Y1OT Michael G. Garwood, Medina, MN 29/4998; Y10T 29/49982; Y10T 29/49888 (US); Michael T. Nelson, Golden Valley, See application file for complete search history. MN (US); Daniel A. Halpern, St. Louis Park, MN (US) (56) References Cited (73) Assignee: Breast-Med, Inc., Golden Valley, MN U.S. PATENT DOCUMENTS (US) (*) Notice: Subject to any disclaimer, the term of this 2,678,195 A * 5/1954 Hunter et al. ..................... 74/87 patent is extended or adjusted under 35 5,016,639 A 5, 1991 Allen U.S.C. 154(b) by 0 days. (Continued) This patent is Subject to a terminal dis FOREIGN PATENT DOCUMENTS claimer. CA 2579914 A1 11/2006 (21) Appl. No.: 14/634,965 EP 1491147 A1 12/2004 (22) Filed: Mar. 2, 2015 (Continued) (65) Prior Publication Data OTHER PUBLICATIONS US 2015/O1 73848A1 Jun. 25, 2015 “U.S. Appl. No. 1 1/281,801. Examiner Interview Summary mailed Related U.S. Application Data Sep. 2, 2009, 4pgs. (63) Continuation of application No. 14/022.539, filed on (Continued) Sep. 10, 2013, now Pat. No. 8,966,735, which is a continuation of application No. 12/762,837, filed on Primary Examiner — Christopher M Koehler Apr. 19, 2010, now Pat. No. 8,544,162, which is a (74) Attorney, Agent, or Firm — Schwegman Lundberg & continuation-in-part of application No. 1 1/281,801, Woessner, P.A. filed on Nov. 17, 2005, now Pat. No. 7,702,378. (51) Int. C. (57) ABSTRACT A6B 9/00 (2006.01) An implantable tissue marker incorporates a contrast agent A6 IK 49/00 (2006.01) sealed within a chamber in a container formed from a solid (Continued) material. The contrast agent is selected to produce a change, (52) U.S. C. Such as an increase, in signal intensity under magnetic reso CPC ................. A61B 19/54 (2013.01); A61B 8/481 nance imaging (MRI). An additional contrast agent may also (2013.01); A61B 17/3468 (2013.01); be sealed within the chamber to provide visibility under another imaging modality, such as computed tomographic (Continued) (CT) imaging or ultrasound imaging. (58) Field of Classification Search CPC ... A61B 8/481; A61 B 17/3468; A61B 19/54; 37 Claims, 6 Drawing Sheets v A. 6 A. US 9.241,773 B2 Page 2 (51) Int. Cl. 6,761,679 B2 7/2004 Sajo et al. A6 IK 49/04 (2006.01) 6,773,408 B1 8, 2004 Acker et al. 6,778,850 B1 8/2004 Adler et al. A6 IK 49/8 (2006.01) 6,862,470 B2 3/2005 Burbank et al. A6 IB 8/08 (2006.01) 6,927.406 B2 8/2005 Zyromski A6 IB 7/34 (2006.01) SS E3 2.58: RE:urbank et al. A6 IK 49/22 (2006.01) 7,010,340 B2 3/2006 Scarantino et al. A6M 3L/00 (2006.01) 7,044,957 B2 5/2006 Foerster et al. GOIR 33/48 (2006.01) 7,047,063 B2 5, 2006 Burbank et al. GOIR 33/56 (2006.01) 76.53.s sy 358 SARE".ag. Cal. ............ 600.414 HOIF 41/02 (2006.01) 7,702.378 B2 * 4/2010 Bolan et al. ................... 600,414 (52) U.S. Cl. 7,792,568 B2 * 9/2010 Zhong et al. .................. 600,431 CPC ........ A61K 49/0002 (2013.01); A61K 49/0447 2: 3: 833, Nissal 69; (2013.01); A61K 49/18 (2013.01); A61 K 88: 5. '58 E. N. O. 29,460 49/223 (2013.01); A61M31/002 (2013.01); 2002/0035324 A1 3/2002 Sirimanne et al. ............ 600,431 A61M31/005 (2013.01); G0IR 33/4812 2002, 0083591 A1 7/2002 GeertSma et al. (2013.01); G0IR 33/4814 (2013.01); G0IR 29:29:395). A 2992 Stegmaier et al. ... 128,899 33/5601 (2013.01); A61B 2019/547 (2013.01); 38885 A. 858 Satyal. 600/407 A61B 2019/5408 (2013.01); A61B 2019/5425 2002/0188196 A1 12/2002 Burbank et al. (2013.01); A61B 2019/5454 (2013.01); A61B 2004/003O262 A1* 2, 2004 Fisher et al. 600/S64 2019/5458 (2013.01); A61B 2019/5466 2004/0176684 A1* 9, 2004 Tabuchi et al. ... 600,424 (2013.01); A61B 2019/5495 (2013.01); HOIF 338E. A. 239: fA, (ao 600,431 41/02 (2013.01); HOIF 41/0253 (2013.01); 200402363.11. A 11/2004 Burbanket al. Y10T 29/49075 (2015.01); Y10T 29/4998 2004/0236212 A1 11/2004 Jones et al. (2015.01); Y10T 29/49888 (2015.01); Y10T 2004/0236213 A1 11/2004 Jones et al. 29/49982 (2015.01) 2005, 000445.6 A1 1/2005 Thomas et al. 2005/002091.6 A1 1/2005 MacFarlane et al. 2005, OO33157 A1 2/2005 Klein et al. (56) References Cited 2005/0059884 A1 3/2005 Kragg 2005/0059888 A1 3/2005 Sirimanne et al. ............ 600,431 U.S. PATENT DOCUMENTS 2005, OO65393 A1 3, 2005 Miller 2005, 0080337 A1* 4/2005 Sirimanne et al. ............ 600,431 5,097.839 A 3/1992 Allen 2005, 0080338 A1* 4/2005 Sirimanne et al. ............ 600,431 5,119,817 A 6/1992 Allen 2005, 0080339 A1 4/2005 Sirimanne et al. ............ 600,431 5,179,955 A 1/1993 Leveen et al. 2005/0085724 A1* 4/2005 Sirimanne et al. ............ 600,431 34::-- I A ck 38 fishereelpinger et al.a .. 378,162 2005/01542932005/0143656 A1*Al 7/20056, 2005 GisselbergBurbank et etal. al. ........... 600,420 5,397.329 A * 3/1995 Allen ............................ 378,205 2005/0205445 A1 9, 2005 Seiler et al. 5,405,402. A 4, 1995 Dye et al. 2005/023.4336 A1 10, 2005 Beckman et al. 5,469,847 A 1 1/1995 Zinreich et al. 2005/0255045 A1 1 1/2005 Woltering 5,609.850 A 3/1997 Deutsch et al. 2006/0036.165 A1 2/2006 Burbank et al. 5,702,128 A 12/1997 Maxim et al. 2006/0058,645 A1 3/2006 Komistek et al. 5,769,861. A 6/1998 Vilsmeier 2006/0058,648 A1 3/2006 Meier et al. 5,782,764 A 7/1998 Werne 2006, 00798.05 A1 4, 2006 Miller et al. 6,128,522. A 10/2000 Acker et al. 2006/0084865 A1 4/2006 Burbank et al. 6,161,034. A 12/2000 Burbank et al. 2006/O122503 A1 6/2006 Burbank et al. 6, 181960 B1 1/2001 Jensen et al. 2006, O155190 A1 7, 2006 Burbank et al. 6.269,148 B1 7/2001 Jessop et al. 2006/0173296 A1 8, 2006 Miller et al. 6,270,464 B1 8/2001 Fulton, III et al. 2006, O293581 A1 12/2006 Plewes et al. 6,333,971 B2 12/2001 McCrory et al. 2007, 0087.026 A1 4, 2007 Field 6,347,241 B2 2/2002 Burbank et al. 2007/0093726 A1 4/2007 Leopold et al. 6.350,244 B1 2/2002 Fisher 2007, 0110665 A1 5, 2007 Bolan et al. 6,356,782 B1 3/2002 Sirimanne et al. 2007, 0118034 A1 5, 2007 Mark 6,371,904 B1 4/2002 Sirimanne et al. 2007. O142725 A1 6, 2007 Hardin et al. 6,374,132 B1 4/2002 Acker et al. 2008/0033286 A1 2/2008 Whitmore et al. 6,394.965 B1 5/2002 Klein 2008/0234572 A1 9, 2008 Jones 6,405,072 B1 6/2002 Cosman 2008/0269603 A1 10, 2008 Nicoson et al. 6.427,081 B1 7/2002 Burbank et al. 2009, O105584 A1 4, 2009 Jones 6,487,438 B1 1 1/2002 Widmarket al. 2010.0030072 A1 2/2010 Casanova et al. ............. 600,431 6,516,211 B1 2/2003 Acker et al. 2010/0287887 A1 11, 2010 Bolan et al. 6,544,185 B2 4/2003 Montegrande 2013/0046164 A1 2/2013 Liu et al. 6,546,279 B1 4/2003 Bova et al. 2013/O150707 A1 6, 2013 C al 6,549,802 B2 4/2003 Thornton ima et al. 6,567,689 B2 5/2003 Burbank et al. 2013/0324946 A1 12/2013 Tobias et al. 6,575.991 B1 6/2003 Chesbrough et al. 2014/0187911 A1 7, 2014 Bolan et al. 6,605,047 B2 8/2003 Zarins et al. 6,632,176 B2 10/2003 McIntire et al. FOREIGN PATENT DOCUMENTS 6,635,064 B2 10/2003 Uetal. 6,656,192 B2 12/2003 Espositio et al. EP 1579878 A1 9, 2005 6,662,041 B2 12/2003 Burbank et al. EP 1847845 A1 10, 2007 6,699,205 B2 3/2004 Fulton, III et al. WO WO-9717103 A1 5, 1997 6,725,083 B1 4/2004 Burbank et al. WO WO-0O24332 A1 5.2000 6,730,042 B2 5/2004 Fulton et al. WO WO-0038579 A2 7, 2000 6,746,661 B2 6/2004 Kaplan WO WO-0230482 A1 4, 2002 US 9.241,773 B2 Page 3 (56) References Cited “U.S. Appl. No. 14/022,539, Final Office Action mailed Jul. 24, 2014'. 7 pgs. FOREIGN PATENT DOCUMENTS “U.S. Appl. No. 14/022,539.
Load more

Recommended publications
  • Investigation of Dosimetric Effects of Radiopaque Fiducial Markers for Use in Proton Beam Therapy with Film Measurements and Monte Carlo Simulations
    Investigation of dosimetric effects of radiopaque fiducial markers for use in proton beam therapy with film measurements and Monte Carlo simulations Zerrin Uludag Thesis for Master of Science in Medical Radiation Physics 2014-04-10 Supervisors: Anders Montelius and Shirin Enger - 2 - ACKNOWLEDGMENTS I would like to express my sincere gratitude to Professor Anders Ahnesjö for helpful advice. - 3 - ABSTRACT Purpose: To estimate the dose perturbation introduced by implanted radiopaque fiducial markers in proton beam therapy (PBT) depending on the shape, orientation and localization of the marker. The aim was also to make a comparative study between the cylindrical proton gold marker (0.6 mm x 4.0 mm), used today in PBT, the photon marker (1.2 mm x 3.0 mm) and the Gold Anchor marker (0.28 mm x 20.0mm), a new type of marker developed by Naslund Medical AB for use in soft tissue. Background: In radiation therapy (RT), fiducial markers are often used in order to facilitate the tumour localization by using image guided radiation therapy (IGRT). However, the use of x-ray opaque markers in PBT can introduce unacceptable underdosage behind the marker in the target resulting in less effective tumour cell kill. Materials and methods: Radiochromic film measurements and Monte Carlo (MC) calculations based on the Geant4 general-purpose simulation toolkit were used in this work for the estimation of the dose perturbation in presence of fiducial gold markers. The experiments were performed at The Svedberg Laboratory (TSL) which offers proton beams with a passive scattering technique. The fiducials were imbedded into Blue wax and the films were stacked behind the wax between thin PMMA slabs.
    [Show full text]
  • Image-Guided Radiation Therapy
    Image-guided Radiation Therapy (IGRT) Image-guided radiation therapy (IGRT) is the use of imaging during radiation therapy to improve the precision and accuracy of treatment delivery. IGRT is used to treat tumors in areas of the body that move, such as the lungs. Radiation therapy machines are equipped with imaging technology to allow your doctor to image the tumor before and during treatment. By comparing these images to the reference images taken during simulation, the patient's position and/or the radiation beams may be adjusted to more precisely target the radiation dose to the tumor. To help align and target the radiation equipment, some IGRT procedures may use fiducial markers, ultrasound, MRI, x-ray images of bone structure, CT scan, 3-D body surface mapping, electromagnetic transponders or colored ink tattoos on the skin. If you are to undergo IGRT, your doctor will likely use CT scanning to conduct a treatment simulation session and to create reference images. Other imaging procedures, such as MRI or PET scan, may be used to help determine the exact shape and location of your tumor, and a special device may be created to help you maintain the same exact position during each treatment. Your doctor will give you specific instructions based on the type of exam being performed. What is Image-Guided Radiation Therapy and how is it used? Image-guided radiation therapy (IGRT) is the use of frequent imaging during a course of radiation therapy for the purpose of improving the precision and accuracy of the delivery of radiation treatment. In IGRT, machines that deliver radiation, such as a linear accelerator (for x-ray or photon) or cyclotron/synchrotron (for proton), are equipped with special imaging technology that allow the physician to image the tumor immediately before or even during the time radiation is delivered, while the patient is positioned on the treatment table.
    [Show full text]
  • Evaluation of the Visibility and Artifacts of 11 Common Fiducial Markers for Image-Guided Stereotactic Body Radiation Therapy in the Abdomen
    Evaluation of the Visibility and Artifacts of 11 Common Fiducial Markers for Image-Guided Stereotactic Body Radiation Therapy in the Abdomen Jordan M. Slagowski, Ph.D.1, Lauren E. Colbert, M.D., MSCR2, Irina M. Cazacu, M.D.3, Ben S. Singh, B.S.3, Rachael Martin, Ph.D.1, Eugene J. Koay, M.D., Ph.D.2, Cullen M. Taniguchi, M.D., Ph.D.2, Albert C. Koong, M.D., Ph.D.2, Manoop S. Bhutani, M.D.3, Joseph M. Herman, M.D., M.S.2, and Sam Beddar, Ph.D.1 1Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA 2Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA 3Department of Gastroenterology Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA Published as: Slagowski JM, Colbert LE, Cazacu IM, et al. Evaluation of the Visibility and Artifacts of 11 Common Fiducial Markers for Image Guided Stereotactic Body Radiation Therapy in the Abdomen [published online ahead of print, 2020 Jan 24]. Pract Radiat Oncol. 2020;S1879-8500(20)30008-4. doi:10.1016/j.prro.2020.01.007 Correspondence to: Sam Beddar, Ph.D. Department of Radiation Physics, The University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd, Unit 94, Houston, TX 77030, USA. Tel: (713) 563-2609; Fax: (713) 563-2479; E-mail: [email protected] Source of financial support / funding: None Author responsible for statistical analysis: Jordan M. Slagowski Correspondence to author responsible for statistical analysis: Jordan M.
    [Show full text]
  • Application of Three-Dimensional Motion Tracking of Low-Activity fiducial Positron-Emitting Markers in Radiation Therapy and Positron Emission Tomography
    Application of three-dimensional motion tracking of low-activity fiducial positron-emitting markers in radiation therapy and positron emission tomography by Marc Chamberland A thesis submitted to the Faculty of Graduate and Postdoctoral Affairs in partial fulfilment of the requirements for the degree of Doctor of Philosophy in Physics Carleton University Ottawa, Ontario ©2015 Marc Chamberland Abstract Patient body motion limits the delivery accuracy of radiotherapy and creates blur- ring artefacts on positron emission tomography (PET) images. Those adverse ef- fects can be mitigated by tracking the patient body motion and using the infor- mation appropriately. A technique that can track the three-dimensional motion of low-activity positron-emitting fiducial markers was developed. The application of this tracking technique, called PeTrack, for respiratory-gated radiotherapy and for motion-compensated PET imaging was evaluated. The feasibility of respiratory-gated radiotherapy using PeTrack was assessed. A respiratory gating interface was developed in LabVIEW to communicate with an Elekta Precise research linear accelerator and toggle the delivery of the beam. Ra- diochromic films were placed in a rod insert of an anthropomorphic dynamic thorax phantom to evaluate the dose distribution of the gated and non-gated delivery of a small square beam. A single low-activity source was used to track the motion of the phantom. Real patient breathing data were used as the basis of the motion of the phantom. Visual and quantitative assessments of the films confirmed that respiratory-gated radiotherapy using real-time tracking based on positron-emitting fiducial markers is achievable. The blurring of the dose distribution due to motion was greatly reduced on the gated deliveries compared to the non-gated cases.
    [Show full text]
  • CT Fluoroscopy–Guided Percutaneous Fiducial Marker
    CLINICAL STUDY CT Fluoroscopy–Guided Percutaneous Fiducial Marker Placement for CyberKnife Stereotactic Radiosurgery: Technical Results and Complications in 222 Consecutive Procedures Christoph G. Trumm, MD, Sophia M. Häußler, Alexander Muacevic, MD, Robert Stahl, MD, Sebastian Stintzing, MD, Philipp M. Paprottka, MD, Frederik Strobl, MD, Tobias F. Jakobs, MD, Maximilian F. Reiser, MD, and Ralf-Thorsten Hoffmann, MD ABSTRACT Purpose: To evaluate technical outcome and safety of computed tomographic (CT) fluoroscopy–guided percutaneous fiducial marker placement before CyberKnife stereotactic radiosurgery. Materials And Methods: Retrospective analysis was performed of 196 patients (106 men) undergoing CT fluoroscopy–guided fiducial marker placement in 222 consecutive procedures under local anesthesia from March 2006 to February 2012. Technical success was defined as fiducial marker location in the tumor or vicinity suitable for CyberKnife radiosurgery evaluated on postinterventional planning CT. Complications were classified per Society of Interventional Radiology (SIR). Results: One hundred ninety-six patients (age, 61.5 y Ϯ 13.1) underwent percutaneous placement of 321 fiducial markers (mean per tumor, 1.2 Ϯ 0.5; range, 1–4) in 37 primary tumors and 227 metastases in the thorax (n ¼ 121), abdomen (n ¼ 122), and bone (n ¼ 21). Fiducial marker placement was technically successful in all procedures: intratumoral localization in 193 (60.1%), at tumor margin in 50 (15.6%), and outside of tumor in 78 cases (24.3%; mean distance to marker, 0.4 cm Ϯ 0.6; range, 0–2.9 cm). Complications were observed in 63 placement procedures (28.4%), including minor self-limiting pneumothorax (n ¼ 21; SIR class B) and self-limiting pulmonary hemorrhage (n ¼ 35; SIR class A), and major pneumothorax requiring thoracostomy/ drainage insertion (n ¼ 14; SIR class D) and systemic toxicity of local anesthetic drug (n ¼ 1; SIR class D).
    [Show full text]
  • AJUR Volume 13 Issue 2 (June 2016)
    Volume 13 | Issue 2 | June 2016 www.ajuronline.org Print Edition ISSN 1536-4585 Online Edition ISSN 2375-8732 Volume 13 | Issue 2 | June 2016 www.ajuronline.org 2 AJUR History and Editorial Board 3 Special Thanks to AJUR’s Sponsors 5 Robust Nonlinear Control of BLDC Motor in Quadcopter Applications Steven T. Elliott & Thomas W. Carr 15 Development of Four-Square Fiducial Markers for Analysis of Paper Analytical Devices Jenna Wilson, Tabitha Ricketts, Ian Bentley & Ewa Misiolek 29 Sensitivity Analysis of Common Input Parameters in Tools for Modeling Energy in Homes Sheikh Tijan Tabban & Nelson Fumo 43 Feeding Anti-Semitism: Representations of Jewish Food Practices in Der ewige Jude Forrest Picher 57 hTERT Suppression via Small Interference RNA in Cervical Cancer Cells Shawn Gray & Douglas Christensen 65 Malate : Quinone Oxidoreductase and Malic Enzyme are required for the Plant Pathogen Pseudomonas syringae pv. tomato DC3000 to Utilize Malate Zabrina Ebert, Preston Jacob, Katrina Jose, Lina Fouad, Katherine Vercellino, Steven Van Dorn, Mahaa Sidiqqi & Eve M. Mellgren 73 Engaging Students in Science through a Nature Hike: A Case of Two Students with ADHD Ashleigh Moore, Kristy Lynn Daniel & Aimée K. Thomas 81 Evaluation of Antiulcer Activity of Laghusoothshekhar (an Ayurvedic Formula) in Pyloric Ligature Induced Gastric Ulcers in Albino Rats Nilofer Sayed & Vandana Barve 87 Using Statistical Approaches to Model Natural Disasters Audrene S. Edwards & Kumer Pial Das 105 Explicit Solution for Cylindrical Heat Conduction Kaitlyn Parsons, Tyler Reichanadter, Andi Vicksman & Harvey Segur 1 American Journal of Undergraduate Research www.ajuronline.org American Journal of Undergraduate Research (AJUR) is a national, peer-reviewed, open-source, quarterly, multidisciplinary student research journal.
    [Show full text]
  • Use of Positron Emission Tomography for Proton Therapy Verification
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 5-2014 USE OF POSITRON EMISSION TOMOGRAPHY FOR PROTON THERAPY VERIFICATION Jongmin Cho Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Nuclear Commons, and the Radiology Commons Recommended Citation Cho, Jongmin, "USE OF POSITRON EMISSION TOMOGRAPHY FOR PROTON THERAPY VERIFICATION" (2014). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 435. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/435 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. USE OF POSITRON EMISSION TOMOGRAPHY FOR PROTON THERAPY VERIFICATION by Jongmin Cho, B.E., M.S. APPROVED: _____________________________________ Supervisory Professor, Geoffrey Ibbott, Ph.D _____________________________________
    [Show full text]
  • Utility of Fiducial Markers for Target Positioning in Proton Radiotherapy
    Radiotherapy and Oncology 133 (2019) 28–34 Contents lists available at ScienceDirect Radiotherapy and Oncology journal homepage: www.thegreenjournal.com Original Article Utility of fiducial markers for target positioning in proton radiotherapy of oesophageal carcinoma ⇑ Rudi Apolle a,b, , Stefan Brückner c, Susanne Frosch d, Maximilian Rehm d, Julia Thiele b,d, Chiara Valentini b,d, Fabian Lohaus b,d, Jana Babatz c, Daniela E. Aust e, Jochen Hampe c, Esther G.C. Troost a,b,d,f,g a Helmholtz-Zentrum Dresden – Rossendorf, Institute of Radiooncology – OncoRay; b OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden – Rossendorf; c Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden; d Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden; e Institute for Pathology and Tumour and Normal Tissue Bank of the University Cancer Center (UCC), University Hospital Carl Gustav Carus, Medical Faculty, Technische Universität Dresden; f German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg; and g National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universitaẗ Dresden, Dresden, Germany, and; Helmholtz Association / Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany article info abstract Article history: Background and purpose: Oesophageal mobility relative to bony anatomy is a major source of geometrical Received 6 September 2018 uncertainty in proton radiotherapy of oesophageal carcinoma. To mitigate this uncertainty we investi- Received in revised form 11 December 2018 gated the use of implanted fiducial markers for direct target verification in terms of safety, visibility, Accepted 17 December 2018 and stability.
    [Show full text]
  • Evaluation of Gold Fiducial Marker Manual Localisation for Magnetic Resonance-Only Prostate Radiotherapy Matteo Maspero* , Peter R
    Maspero et al. Radiation Oncology (2018) 13:105 https://doi.org/10.1186/s13014-018-1029-7 RESEARCH Open Access Evaluation of gold fiducial marker manual localisation for magnetic resonance-only prostate radiotherapy Matteo Maspero* , Peter R. Seevinck, Nicole J. W. Willems, Gonda G. Sikkes, Geja J. de Kogel, Hans C. J. de Boer, Jochem R. N. van der Voort van Zyp and Cornelis A. T. van den Berg Abstract Background: The use of intraprostatic gold fiducial markers (FMs) ensures highly accurate and precise image-guided radiation therapy for patients diagnosed with prostate cancer thanks to the ease of localising FMs on photon-based imaging, like Computed Tomography (CT) images. Recently, Magnetic Resonance (MR)-only radiotherapy has been proposed to simplify the workflow and reduce possible systematic uncertainties. A critical, determining factor in the accuracy of such an MR-only simulation will be accurate FM localisation using solely MR images. Purpose: The aim of this study is to evaluate the performances of manual MR-based FM localisation within a clinical environment. Methods: We designed a study in which 5 clinically involved radiation therapy technicians (RTTs) independently localised the gold FMs implanted in 16 prostate cancer patients in two scenarios: employing a single MR sequence or a combination of sequences. Inter-observer precision and accuracy were assessed for the two scenarios for localisation in terms of 95% limit of agreement on single FMs (LoA)/ centre of mass (LoACM) and inter-marker distances (IDs), respectively. Results: The number of precisely located FMs (LoA<2 mm) increased from 38/48 to 45/48 FMs when localisation was performed using multiple sequences instead of single one.
    [Show full text]
  • Automatic Coregistration of Volumetric Images Based on Implanted Fiducial
    Automatic coregistration of volumetric images based on implanted fiducial markers ͒ Martin Kocha Oncology Care Systems Group, Siemens Medical Solutions USA, Inc., 4040 Nelson Avenue, Concord, California 94520 and Chair of Pattern Recognition, Friedrich-Alexander-University Erlangen-Nuremberg, Martensstr. 3, 91058 Erlangen, Germany Jonathan S. Maltz Oncology Care Systems Group, Siemens Medical Solutions USA, Inc., 4040 Nelson Avenue, Concord, California 94520 Serge J. Belongie Department of Computer Science and Engineering, University of California, San Diego, 9500 Gilman Drive, Mail Code 0404, La Jolla, California 92093 Bijumon Gangadharan, Supratik Bose, Himanshu Shukla, and Ali R. Bani-Hashemi Oncology Care Systems Group, Siemens Medical Solutions USA, Inc., 4040 Nelson Avenue, Concord, California 94520 ͑Received 29 February 2008; revised 23 July 2008; accepted for publication 2 August 2008; published 16 September 2008͒ The accurate delivery of external beam radiation therapy is often facilitated through the implanta- tion of radio-opaque fiducial markers ͑gold seeds͒. Before the delivery of each treatment fraction, seed positions can be determined via low dose volumetric imaging. By registering these seed locations with the corresponding locations in the previously acquired treatment planning computed tomographic ͑CT͒ scan, it is possible to adjust the patient position so that seed displacement is accommodated. The authors present an unsupervised automatic algorithm that identifies seeds in both planning and pretreatment images and subsequently determines a rigid geometric transforma- tion between the two sets. The algorithm is applied to the imaging series of ten prostate cancer patients. Each test series is comprised of a single multislice planning CT and multiple megavoltage conebeam ͑MVCB͒ images. Each MVCB dataset is obtained immediately prior to a subsequent treatment session.
    [Show full text]
  • Multimodal Imaging Fiducial Markers for Kinematic Measurement of Joint Models
    Asian Biomedicine Vol. 7 No. 4 August 2013; 509-516 DOI: 10.5372/1905-7415.0704.205 Brief communication (Original) Multimodal imaging fiducial markers for kinematic measurement of joint models Jae Won Youa, Yeon Soo Leeb, Hong Moon Sohna aDepartment of Orthopaedic Surgery, Chosun University Hospital, bDepartment of Biomedical Engineering, Catholic University of Daegu, Gyungbuk 712-702, Republic of Korea Background: Fiducial markers are objects placed in the field of view of an imaging system for use as a point of reference or a measure. There is no information regarding suitable markers for joint models. Objectives: We compared the fiducial markers commonly used in X-ray, CT, and MRI imaging modalities. Methods: The markers tested were plastic balls, ceramic balls, passive reflective balls, liquid-filled balls, and steel balls. The balls were scanned using X-ray, CT, and MRI systems. The scanned X-ray images were reviewed if it the markers are able to be expressed. The tomographic images of CT and MRI were converted into 3D ball models and then the reconstructed shapes and dimensions of the balls were examined. The dimensional accuracy of expression and reconstruction was calculated in terms of the mean and the standard deviation. Results: There was no marker that can be expressed in all the imaging modalities. Alternatively, we propose a synthetic marker that is composed of a hard sphere and a fat tissue wrapping. The hard ball is for X-ray and CT imaging, while the fat tissue is for MRI imaging. Conclusion: A synthetic marker composed of a hard sphere and a fat tissue wrapping can a multimodal fiducial marker.
    [Show full text]